ArticleVaccines2025
Nirsevimab Prophylaxis for Reduction of Respiratory Syncytial Virus Complications in Hospitalised Infants: The Multi-Centre Study During the 2023-2024 Season in Andalusia, Spain (NIRSEGRAND).
Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of a single dose of nirsevimab against respiratory syncytial virus infection in infants: a meta-analysis and time-to-event analysis.Italian journal of pediatrics · 2025Pooled it
- Pooled it
- Acute viral bronchiolitis before and after implementation ofThe Lancet regional health. Europe · 2026Article
- Impact of regional heterogeneity of RSV infection prophylaxis on bronchiolitis in Italy.Italian journal of pediatrics · 2026Observational
- Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns.JAMA · 2026Article
- The Impact of Nirsevimab on the Transport of Critically Ill Children.Children (Basel, Switzerland) · 2026Article
- Real-world impact of nirsevimab on the epidemiology and severity of pediatric respiratory syncytial virus infections: a three-season cohort study in Italy.European journal of pediatrics · 2026Article
- Review
- Impact of universal nirsevimab prophylaxis on clinical and ultrasound presentations of lower respiratory tract infections in hospitalized pediatric patients.European journal of pediatrics · 2025Observational
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNirsevimab was indicated in a population level for all infants < 6 months during the 2023-2024 season in Andalusia (southern Spain). Our aim was to analyse the effect of nirsevimab in the reduction in complications in infants hospitalised for RSV bronchiolitis.
methodsA retrospective observational cohort study was conducted in nine relevant hospitals from all provinces of Andalusia, a region with over 9 million inhabitants. The study sample included 222 children, divided into two groups: infants administered with nirsevimab for passive immunisation (exposure) and infants not administered with nirsevimab. Clinical outcomes were analysed, including the use of respiratory support, the need for admission to paediatric intensive care unit (PICU), and duration of hospitalisation. Bivariate analyses were performed, and multivariable logistic regression models were designed to calculate adjusted odds ratios (ORa), and Cox regression models to calculate adjusted hazard ratios (HRa).
resultsBivariate analysis showed an association between passive immunisation with nirsevimab and a lower frequency of numerous outcomes. After adjustment for relevant covariates, multivariable models showed that the exposure (nirsevimab) reduced nasal cannula use by 64% (13-85%), invasive or non-invasive mechanical ventilation by 48% (1-73%), PICU admission by 54% (14-75%), length of hospitalisation by 30% (8-47%), and length of nasal cannula by 31% (7-49%). A higher risk of co-infection was observed in those immunised (aOR = 3.42, 95%CI: 1.52-7.68).
conclusionsPassive immunisation with nirsevimab may decrease the severity of RSV bronchiolitis in infants requiring hospitalisation, thus contributing tertiary prevention that extends beyond the prevention of RSV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.